Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center.
Lung Cancer
; 157: 79-84, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1225327
ABSTRACT
INTRODUCTION:
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has spread worldwide in 2020 leading the World Health Organization to declare a pandemic. Patients with thoracic cancers have been reported at higher risk to develop severe disease, and die from COVID-19. In this setting, clinical practice recommendations for the management of patients were published. We report here how these guidelines were implemented in a routine practice setting.METHODS:
We retrospectively collected the characteristics, treatment regimen and modification, as well as COVID-19 status and death for all patients with thoracic malignancies scheduled for an appointment at Institute Curie from March 23rd to April 17th 2020.RESULTS:
A total of 339 patients were included. Treatment strategy was modified for a total of 110 (32 %) patients because of COVID-19; these modifications were in accordance with guidelines for 92 % of patients. The majority of dose modifications were related to immune checkpoint inhibitors, for which switch to flat dosing every 4-6 weeks was made. A total of 5 (1.5 %) patients were diagnosed with COVID-19 disease, 1 of whom died from disease complication.CONCLUSION:
Our study provides a unique insight in the decision making for patients with thoracic malignancies in the setting of COVID-19 outbreak, showing how guidelines were implemented in the clinic, and what may be optimized in the clinical practice of thoracic oncology in the future.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thoracic Neoplasms
/
COVID-19
/
Lung Neoplasms
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Lung Cancer
Journal subject:
Neoplasms
Year:
2021
Document Type:
Article
Affiliation country:
J.lungcan.2021.05.007
Similar
MEDLINE
...
LILACS
LIS